These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17565157)

  • 1. Prostate cancer progression and survival in BRCA2 mutation carriers.
    Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H
    J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
    Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
    J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA2 mutation carriers, reproductive factors and breast cancer risk.
    Tryggvadottir L; Olafsdottir EJ; Gudlaugsdottir S; Thorlacius S; Jonasson JG; Tulinius H; Eyfjord JE
    Breast Cancer Res; 2003; 5(5):R121-8. PubMed ID: 12927042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
    Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
    J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.
    Horsburgh S; Matthew A; Bristow R; Trachtenberg J
    Prostate; 2005 Oct; 65(2):124-9. PubMed ID: 15880530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
    Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
    Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.
    Thorne H; Willems AJ; Niedermayr E; Hoh IM; Li J; Clouston D; Mitchell G; Fox S; Hopper JL; ; Bolton D
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1002-10. PubMed ID: 21733824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
    Tryggvadottir L; Olafsdottir EJ; Olafsdottir GH; Sigurdsson H; Johannsson OT; Bjorgvinsson E; Alexiusdottir K; Stefansson OA; Agnarsson BA; Narod SA; Eyfjord JE; Jonasson JG
    Breast Cancer Res Treat; 2013 Jul; 140(2):375-84. PubMed ID: 23857704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer as a second primary in patients with prostate cancer--estrogen treatment or association with family history of cancer?
    Karlsson CT; Malmer B; Wiklund F; Grönberg H
    J Urol; 2006 Aug; 176(2):538-43. PubMed ID: 16813884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families.
    Barkardottir RB; Sarantaus L; Arason A; Vehmanen P; Bendahl PO; Kainu T; Syrjäkoski K; Krahe R; Huusko P; Pyrhönen S; Holli K; Kallioniemi OP; Egilsson V; Kere J; Nevanlinna H
    Eur J Hum Genet; 2001 Oct; 9(10):773-9. PubMed ID: 11781689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.
    Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
    Cancer; 2007 Mar; 109(6):1192-202. PubMed ID: 17311344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Segregation analysis of 389 Icelandic pedigrees with Breast and prostate cancer.
    Baffoe-Bonnie AB; Kiemeney LA; Beaty TH; Bailey-Wilson JE; Schnell AH; Sigvaldason H; Olafsdóttir G; Tryggvadóttir L; Tulinius H
    Genet Epidemiol; 2002 Nov; 23(4):349-63. PubMed ID: 12432503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
    J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
    Willems AJ; Dawson SJ; Samaratunga H; De Luca A; Antill YC; Hopper JL; Thorne HJ;
    Clin Cancer Res; 2008 May; 14(10):2953-61. PubMed ID: 18445692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.
    Syamala V; Syamala VS; Sreeja L; Raveendran PB; Vijayalekshmi RV; Sheeja VR; Santhi S; Kuttan R; Abraham EK; Ankathil R
    J Exp Ther Oncol; 2008; 7(3):227-36. PubMed ID: 19066131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
    Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
    Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.